Income Statement Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 28/09/2026 BST			5-day change	1st Jan Change
35.36 ^USD	+0.11%		+1.93%	+14.81%

09-24	AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma	MT
09-24	Hansa Biopharma brings in two new board members	FW

c4.wc16SeTxhFklhzL44GVgaT5cGBOa5ekJ65VcuA3GVyY.p6AgHL6F4S8WvkKZshIuGE0GXmrCk4FlxvMe4EOuNUnz_Et7vKCxGFXNaw

Published financial data: GENMAB A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (USD)
Revenues	8.48B	14.6B	16.47B	21.53B	3.72B
Total Revenues	8.48B	14.6B	16.47B	21.53B	3.72B
Cost of Goods Sold, Total	-	-	226M	985M	238M
Gross Profit	8.48B	14.6B	16.25B	20.54B	3.48B
Selling General & Admin Expenses, Total	1.28B	2.68B	3.3B	3.79B	626M
R&D Expenses	4.18B	5.52B	7.63B	9.67B	1.61B
Other Operating Expenses, Total	5.46B	8.2B	10.93B	13.46B	2.23B
Operating Income	3.02B	6.4B	5.32B	7.08B	1.25B
Interest Expense, Total	-13M	-21M	-27M	-120M	-61M
Interest And Investment Income	197M	324M	939M	995M	138M
Net Interest Expenses	184M	303M	912M	875M	77M
Currency Exchange Gains (Loss)	1.47B	1.03B	-889M	1.34B	-3M
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	4.67B	7.73B	5.34B	9.29B	1.32B
Merger & Related Restructuring Charges	-	-	-	-300M	-185M
Gain (Loss) On Sale Of Investments	-689M	-659M	293M	247M	65M
Asset Writedown	-	-38M	-	-76M	-
EBT, Incl. Unusual Items	3.98B	7.04B	5.64B	9.16B	1.2B
Income Tax Expense	975M	1.51B	1.28B	1.32B	241M
Earnings From Continuing Operations	3.01B	5.52B	4.35B	7.84B	963M
Net Income to Company	3.01B	5.52B	4.35B	7.84B	963M
Net Income - (IS)	3.01B	5.52B	4.35B	7.84B	963M
Net Income to Common Incl Extra Items	3.01B	5.52B	4.35B	7.84B	963M
Net Income to Common Excl. Extra Items	3.01B	5.52B	4.35B	7.84B	963M
Per Share Items
Net EPS - Basic	46	84.45	66.64	122.21	15.49
Basic EPS - Continuing Operations	46	84.45	66.64	122.21	15.49
Basic Weighted Average Shares Outstanding	65.4M	65.39M	65.31M	64.19M	62.15M
Net EPS - Diluted	45.54	83.65	66.02	121.36	15.37
Diluted EPS - Continuing Operations	45.54	83.65	66.02	121.36	15.37
Diluted Weighted Average Shares Outstanding	66.05M	66.01M	65.91M	64.63M	62.69M
Normalized Basic EPS	44.65	73.91	51.14	90.49	13.31
Normalized Diluted EPS	44.21	73.21	50.67	89.86	13.2
American Depositary Receipts Ratio (ADR)	0.1	0.1	0.1	0.1	0.1
Supplemental Items
EBITDA	3.27B	6.72B	5.56B	7.39B	1.29B
EBITA	3.1B	6.46B	5.38B	7.16B	1.25B
EBIT	3.02B	6.4B	5.32B	7.08B	1.25B
EBITDAR	3.27B	-	-	-	-
Effective Tax Rate - (Ratio)	24.48	21.51	22.8	14.4	20.02
Current Domestic Taxes	968M	1.5B	-	-	-
Total Current Taxes	968M	1.5B	1.3B	1.8B	256M
Deferred Domestic Taxes	7M	15M	-	-	-
Total Deferred Taxes	7M	15M	-16M	-479M	-12M
Normalized Net Income	2.92B	4.83B	3.34B	5.81B	828M
Interest on Long-Term Debt	13M	21M	27M	120M	61M
Supplemental Operating Expense Items
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	4.18B	5.56B	7.63B	9.75B	1.61B
Net Rental Expense, Total	1M	-	-	-	-
Imputed Operating Lease Interest Expense	280K	-	-	-	-
Imputed Operating Lease Depreciation	720K	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., Other (Total)	310M	439M	586M	721M	128M
Total Stock-Based Compensation	310M	439M	586M	721M	128M

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (USD)
Assets
Cash And Equivalents	8.96B	9.89B	14.87B	9.86B	1.72B
Short Term Investments	10.38B	12.43B	13.27B	11.24B	-
Total Cash And Short Term Investments	19.34B	22.32B	28.14B	21.1B	1.72B
Accounts Receivable, Total	3.37B	5.91B	4.95B	6.59B	1.11B
Other Receivables	31M	143M	-	101M	40M
Total Receivables	3.4B	6.05B	4.95B	6.69B	1.15B
Inventory	-	-	57M	62M	18M
Total Current Assets	22.74B	28.38B	33.14B	27.85B	2.88B
Gross Property Plant And Equipment	1.34B	1.82B	2.32B	2.73B	437M
Accumulated Depreciation	-368M	-495M	-676M	-837M	-157M
Net Property Plant And Equipment	975M	1.32B	1.64B	1.89B	280M
Long-term Investments	371M	133M	134M	228M	37M
Goodwill	-	-	-	2.54B	355M
Other Intangibles, Total	254M	146M	101M	12.34B	9.12B
Accounts Receivable Long-Term	27M	48M	62M	52M	22M
Deferred Tax Assets Long-Term	264M	252M	212M	908M	171M
Total Assets	24.63B	30.28B	35.29B	45.81B	12.87B
Liabilities
Accounts Payable, Total	350M	-	-	-	-
Accrued Expenses, Total	296M	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	273M
Current Portion of Leases	62M	74M	90M	92M	18M
Current Income Taxes Payable	-	-	54M	1.71B	43M
Unearned Revenue Current, Total	26M	33M	33M	24M	24M
Other Current Liabilities	834M	1.72B	2.31B	3.48B	1.07B
Total Current Liabilities	1.57B	1.82B	2.48B	5.31B	1.43B
Long-Term Debt	-	-	-	-	5B
Long-Term Leases	363M	523M	680M	937M	134M
Unearned Revenue Non Current	487M	480M	480M	480M	95M
Deferred Tax Liability Non Current	-	-	-	2.36B	364M
Other Non Current Liabilities	13M	11M	35M	30M	5M
Total Liabilities	2.43B	2.84B	3.68B	9.11B	7.03B
Common Stock, Total	66M	66M	66M	66M	10M
Additional Paid In Capital	12.03B	12.31B	12.46B	12.59B	1.92B
Retained Earnings	10.02B	14.97B	19.02B	23.55B	4.1B
Comprehensive Income and Other	81M	98M	60M	490M	-181M
Total Common Equity	22.2B	27.44B	31.61B	36.7B	5.85B
Total Equity	22.2B	27.44B	31.61B	36.7B	5.85B
Total Liabilities And Equity	24.63B	30.28B	35.29B	45.81B	12.87B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	65.43M	65.37M	65.33M	63.54M	61.62M
ECS Total Common Shares Outstanding	65.43M	65.37M	65.33M	63.54M	61.62M
Book Value / Share	339.23	419.77	483.85	577.54	94.89
Tangible Book Value	21.94B	27.3B	31.51B	21.82B	-3.63B
Tangible Book Value Per Share	335.35	417.54	482.3	343.39	-58.93
Total Debt	425M	597M	770M	1.03B	5.43B
Net Debt	-18.91B	-21.73B	-27.36B	-20.07B	3.71B
Debt Equivalent Oper. Leases	8M	-	-	-	-
Account Code - Inventory Valuation	3	3	3	5	5
Inventories - Raw Materials, Total	-	-	14M	4M	6M
Inventories - Finished Goods, Total	-	-	59M	79M	13M
Machinery, Total	537M	649M	908M	991M	175M
Full Time Employees	1.21K	1.66K	2.2K	2.63K	2.97K

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (USD)
Net Income	3.01B	5.52B	4.35B	7.84B	963M
Depreciation & Amortization - CF	220M	328M	185M	335M	55M
Amortization of Goodwill and Intangible Assets - (CF)	84M	70M	55M	78M	2M
Depreciation & Amortization, Total	304M	398M	240M	413M	57M
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	14M
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	689M	659M	-293M	-247M	-65M
Asset Writedown & Restructuring Costs	-	38M	-	115M	32M
Stock-Based Compensation (CF)	310M	439M	586M	721M	128M
Other Operating Activities, Total	-1.31B	-1.21B	1.13B	-337M	-168M
Change In Accounts Receivable	-1.07B	-2.21B	797M	-1.59B	-166M
Change In Inventories	-	-	-57M	-5M	-9M
Change In Accounts Payable	304M	283M	622M	857M	400M
Change in Unearned Revenues	-	-	-	-	-
Cash from Operations	2.23B	3.91B	7.38B	7.77B	1.19B
Capital Expenditure	-252M	-317M	-366M	-187M	-37M
Cash Acquisitions	-	-	-	-12.25B	-7.22B
Sale (Purchase) of Intangible assets	-	-	-10M	-117M	-18M
Investment in Marketable and Equity Securities, Total	-709M	-2.44B	-906M	2.64B	1.63B
Cash from Investing	-961M	-2.76B	-1.28B	-9.91B	-5.64B
Long-Term Debt Issued, Total	-	-	-	-	5.5B
Total Debt Issued	-	-	-	-	5.5B
Long-Term Debt Repaid, Total	-58M	-73M	-91M	-60M	-13M
Total Debt Repaid	-58M	-73M	-91M	-60M	-13M
Issuance of Common Stock	135M	280M	152M	129M	23M
Repurchase of Common Stock	-497M	-996M	-667M	-3.99B	-448M
Other Financing Activities, Total	-	-	-	-	-273M
Cash from Financing	-420M	-789M	-606M	-3.92B	4.79B
Foreign Exchange Rate Adjustments	850M	574M	-518M	1.05B	3M
Net Change in Cash	1.7B	936M	4.97B	-5.01B	335M
Supplemental Items
Cash Interest Paid	12M	16M	25M	35M	10M
Cash Income Tax Paid (Refund)	742M	1.58B	1.07B	343M	460M
Levered Free Cash Flow	1.85B	2.09B	5.29B	6.25B	1.07B
Unlevered Free Cash Flow	1.86B	2.1B	5.31B	6.33B	1.11B
Change In Net Working Capital	391M	2.41B	-1.54B	-1.07B	-181M
Net Debt Issued / Repaid	-58M	-73M	-91M	-60M	5.49B

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (USD)
Profitability
Return on Assets	8.24	14.56	10.17	10.91	8.1
Return on Total Capital	8.97	15.78	11.04	12.62	9.44
Return On Equity %	14.56	22.25	14.78	22.97	17.53
Return on Common Equity	14.56	22.25	14.78	22.97	17.53
Margin Analysis
Gross Profit Margin %	100	100	98.63	95.42	93.6
SG&A Margin	15.13	18.34	20.01	17.61	16.83
EBITDA Margin %	38.5	46.04	33.76	34.33	34.68
EBITA Margin %	36.57	44.3	32.63	33.25	33.66
EBIT Margin %	35.58	43.82	32.3	32.89	33.6
Income From Continuing Operations Margin %	35.46	37.83	26.42	36.44	25.89
Net Income Margin %	35.46	37.83	26.42	36.44	25.89
Net Avail. For Common Margin %	35.46	37.83	26.42	36.44	25.89
Normalized Net Income Margin	34.43	33.11	20.27	26.98	22.24
Levered Free Cash Flow Margin	21.8	14.33	32.13	29.05	28.71
Unlevered Free Cash Flow Margin	21.9	14.42	32.24	29.39	29.74
Asset Turnover
Asset Turnover	0.37	0.53	0.5	0.53	0.39
Fixed Assets Turnover	9.91	12.71	11.12	12.19	13.65
Receivables Turnover (Average Receivables)	2.91	3.15	3.09	3.73	3.66
Inventory Turnover (Average Inventory)	-	-	-	16.55	17.63
Short Term Liquidity
Current Ratio	14.5	15.57	13.34	5.25	2.02
Quick Ratio	14.5	15.57	13.32	5.24	2.01
Operating Cash Flow to Current Liabilities	1.42	2.15	2.97	1.46	0.83
Days Sales Outstanding (Average Receivables)	125.44	116	118.08	98.08	99.84
Days Outstanding Inventory (Average Inventory)	-	-	-	22.11	20.7
Long Term Solvency
Total Debt/Equity	1.91	2.18	2.44	2.8	92.8
Total Debt / Total Capital	1.88	2.13	2.38	2.73	48.13
LT Debt/Equity	1.64	1.91	2.15	2.55	87.82
Long-Term Debt / Total Capital	1.6	1.87	2.1	2.48	45.55
Total Liabilities / Total Assets	9.87	9.37	10.43	19.89	54.58
EBIT / Interest Expense	232.15	304.52	197.07	58.99	20.49
EBITDA / Interest Expense	255.54	323.48	205.96	62.43	21.43
(EBITDA - Capex) / Interest Expense	236.15	308.38	192.41	60.88	20.82
Total Debt / EBITDA	0.13	0.09	0.14	0.14	4.15
Net Debt / EBITDA	-5.69	-3.2	-4.92	-2.68	2.84
Total Debt / (EBITDA - Capex)	0.14	0.09	0.15	0.14	4.27
Net Debt / (EBITDA - Capex)	-6.16	-3.36	-5.27	-2.75	2.92
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-16.11	72.07	13.57	30.67	19.19
Gross Profit, 1 Yr. Growth %	-16.11	72.07	12.02	26.42	16.92
EBITDA, 1 Yr. Growth %	-50.25	105.73	-14.72	33.66	22.62
EBITA, 1 Yr. Growth %	-51.86	108.41	-15.67	33.93	22.99
EBIT, 1 Yr. Growth %	-52.36	111.9	-15.61	33.04	23.15
Earnings From Cont. Operations, 1 Yr. Growth %	-36.78	83.58	-20.18	80.24	-15
Net Income, 1 Yr. Growth %	-36.78	83.58	-20.18	80.24	-15
Normalized Net Income, 1 Yr. Growth %	-7.54	65.5	-30.07	73.9	7.38
Diluted EPS Before Extra, 1 Yr. Growth %	-36.93	83.68	-20.06	83.82	-12.32
Accounts Receivable, 1 Yr. Growth %	36.7	75.53	-13.39	33.21	20.48
Inventory, 1 Yr. Growth %	-	-	-	8.77	100
Net Property, Plant and Equip., 1 Yr. Growth %	32.47	35.59	24.13	15.23	5.66
Total Assets, 1 Yr. Growth %	16.48	22.95	17.17	29.82	100.7
Tangible Book Value, 1 Yr. Growth %	16.82	24.4	16.12	-30.75	-218.89
Common Equity, 1 Yr. Growth %	16.08	23.63	15.86	16.09	13.82
Cash From Operations, 1 Yr. Growth %	-65.37	75.58	88.65	5.3	5.33
Capital Expenditures, 1 Yr. Growth %	-17.92	25.79	15.46	-48.91	37.04
Levered Free Cash Flow, 1 Yr. Growth %	-60.57	13.12	163.04	17.48	16.72
Unlevered Free Cash Flow, 1 Yr. Growth %	-60.45	13.33	162.17	17.92	19.42
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	25.73	20.14	39.9	21.82	24.76
Gross Profit, 2 Yr. CAGR %	25.73	20.14	38.94	19	21.54
EBITDA, 2 Yr. CAGR %	8.45	1.34	32.93	6.18	26.83
EBITA, 2 Yr. CAGR %	6.46	0.33	33.05	5.69	27.1
EBIT, 2 Yr. CAGR %	6.96	0.65	34.23	6.28	27.25
Earnings From Cont. Operations, 2 Yr. CAGR %	17.84	7.73	21.32	19.95	23.54
Net Income, 2 Yr. CAGR %	17.84	7.73	21.32	19.95	23.54
Normalized Net Income, 2 Yr. CAGR %	28.04	23.97	7.7	10.56	25.7
Diluted EPS Before Extra, 2 Yr. CAGR %	15.68	7.63	21.44	21.22	26.66
Accounts Receivable, 2 Yr. CAGR %	6.12	54.9	21.21	7.41	23.17
Inventory, 2 Yr. CAGR %	-	-	-	-	50
Net Property, Plant and Equip., 2 Yr. CAGR %	53.46	34.02	29.73	19.6	7.12
Total Assets, 2 Yr. CAGR %	27.52	19.67	19.71	23.33	56.86
Tangible Book Value, 2 Yr. CAGR %	27.12	20.55	19.83	-10.33	-11.84
Common Equity, 2 Yr. CAGR %	25.7	19.8	19.34	15.98	11.69
Cash From Operations, 2 Yr. CAGR %	29.62	-22.02	82	40.94	5.23
Capital Expenditures, 2 Yr. CAGR %	78.6	1.62	20.51	-23.19	-16.45
Levered Free Cash Flow, 2 Yr. CAGR %	68.36	-33.11	76.54	71.59	17.18
Unlevered Free Cash Flow, 2 Yr. CAGR %	68.16	-32.95	76.4	71.64	18.77
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	41.01	39.59	17.67	36.75	17.72
Gross Profit, 3 Yr. CAGR %	41.01	39.59	17.13	34.63	15.15
EBITDA, 3 Yr. CAGR %	30.55	34.25	-5.28	32.92	7.77
EBITA, 3 Yr. CAGR %	29.15	33.18	-5.75	33.07	7.52
EBIT, 3 Yr. CAGR %	29.8	34.33	-5.54	33.83	8.26
Earnings From Cont. Operations, 3 Yr. CAGR %	26.9	36.61	-2.93	38.43	3.96
Net Income, 3 Yr. CAGR %	26.9	36.61	-2.93	38.43	3.96
Normalized Net Income, 3 Yr. CAGR %	42.25	39.47	2.03	26.35	3.47
Diluted EPS Before Extra, 3 Yr. CAGR %	24.27	34.96	-2.94	39.43	5.78
Accounts Receivable, 3 Yr. CAGR %	36.39	25.5	26.17	25.09	7.39
Net Property, Plant and Equip., 3 Yr. CAGR %	81.9	47.26	30.64	24.71	10.45
Total Assets, 3 Yr. CAGR %	42.78	25.98	18.62	22.99	39.57
Tangible Book Value, 3 Yr. CAGR %	42.74	26.21	18.82	-0.19	-5.23
Common Equity, 3 Yr. CAGR %	40.43	25.01	18.24	18.25	10.88
Cash From Operations, 3 Yr. CAGR %	29.96	43.42	4.68	51.65	24.47
Capital Expenditures, 3 Yr. CAGR %	51.83	58.91	6.03	-9.47	-9.45
Levered Free Cash Flow, 3 Yr. CAGR %	471.03	47.46	4.23	54.4	47.35
Unlevered Free Cash Flow, 3 Yr. CAGR %	471.86	47.44	4.29	54.77	48.52
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	36.1	43.9	40.35	32.03	18.54
Gross Profit, 5 Yr. CAGR %	36.1	43.9	39.96	30.8	16.98
EBITDA, 5 Yr. CAGR %	24.46	36.58	30.52	21.62	4.63
EBITA, 5 Yr. CAGR %	23.4	35.76	30.14	21.2	4.4
EBIT, 5 Yr. CAGR %	23.44	36.16	30.99	21.83	4.72
Earnings From Cont. Operations, 5 Yr. CAGR %	20.44	37.99	24.21	29.35	5.18
Net Income, 5 Yr. CAGR %	20.44	37.99	24.21	29.35	5.18
Normalized Net Income, 5 Yr. CAGR %	32.61	47.55	26.91	26.67	10.85
Diluted EPS Before Extra, 5 Yr. CAGR %	18.83	36.32	22.71	28.96	6.25
Accounts Receivable, 5 Yr. CAGR %	28.11	59.14	30.11	17.12	23.49
Net Property, Plant and Equip., 5 Yr. CAGR %	97.81	63.42	58.9	35.5	19.33
Total Assets, 5 Yr. CAGR %	36.28	35.61	33.06	24.78	31.1
Tangible Book Value, 5 Yr. CAGR %	36.41	34.73	33.1	9.95	4.22
Common Equity, 5 Yr. CAGR %	35.68	34.34	31.58	21.17	14.23
Cash From Operations, 5 Yr. CAGR %	46.72	19.74	48.7	42.43	3.24
Capital Expenditures, 5 Yr. CAGR %	83.07	29.07	38.43	18.81	-5.18
Levered Free Cash Flow, 5 Yr. CAGR %	85.22	12.87	251.04	57.15	7.76
Unlevered Free Cash Flow, 5 Yr. CAGR %	85.44	12.98	251.26	57.31	8.49